A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Abb Vie Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 60,076 shares of ABBV stock, worth $10.5 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
60,076
Previous 60,013 0.1%
Holding current value
$10.5 Million
Previous $10.3 Million 15.25%
% of portfolio
0.11%
Previous 0.1%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$163.84 - $199.33 $10,321 - $12,557
63 Added 0.1%
60,076 $11.9 Million
Q2 2024

Jul 17, 2024

BUY
$154.79 - $180.76 $254,319 - $296,988
1,643 Added 2.81%
60,013 $10.3 Million
Q1 2024

Apr 23, 2024

SELL
$159.82 - $182.1 $137,125 - $156,241
-858 Reduced 1.45%
58,370 $10.6 Million
Q4 2023

Feb 01, 2024

SELL
$137.6 - $154.97 $277,401 - $312,419
-2,016 Reduced 3.29%
59,228 $9.18 Million
Q3 2023

Nov 03, 2023

SELL
$133.59 - $154.65 $543,043 - $628,652
-4,065 Reduced 6.22%
61,244 $9.13 Million
Q2 2023

Aug 01, 2023

SELL
$132.51 - $164.9 $44,788 - $55,736
-338 Reduced 0.51%
65,309 $8.8 Million
Q1 2023

May 02, 2023

SELL
$144.61 - $166.54 $239,763 - $276,123
-1,658 Reduced 2.46%
65,647 $10.5 Million
Q4 2022

Mar 02, 2023

BUY
$138.31 - $165.87 $6,915 - $8,293
50 Added 0.07%
67,305 $10.9 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $31,811 - $38,150
230 Added 0.34%
67,255 $9.99 Million
Q3 2022

Oct 25, 2022

SELL
$134.21 - $153.93 $41,068 - $47,102
-306 Reduced 0.45%
67,025 $9 Million
Q2 2022

Jul 26, 2022

BUY
$137.62 - $174.96 $103,490 - $131,569
752 Added 1.13%
67,331 $10.3 Million
Q1 2022

Apr 13, 2022

SELL
$131.98 - $163.75 $430,650 - $534,316
-3,263 Reduced 4.67%
66,579 $10.8 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $668,107 - $845,348
-6,219 Reduced 8.18%
69,842 $9.46 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $58,520 - $66,429
550 Added 0.73%
76,061 $8.21 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $145,505 - $162,101
1,383 Added 1.87%
75,511 $8.51 Million
Q1 2021

Apr 14, 2021

SELL
$102.3 - $112.62 $618,403 - $680,787
-6,045 Reduced 7.54%
74,128 $8.02 Million
Q4 2020

Jan 14, 2021

SELL
$80.49 - $108.67 $20,927 - $28,254
-260 Reduced 0.32%
80,173 $8.59 Million
Q3 2020

Oct 15, 2020

SELL
$85.91 - $100.83 $281,870 - $330,823
-3,281 Reduced 3.92%
80,433 $7.05 Million
Q2 2020

Jul 30, 2020

SELL
$73.37 - $98.18 $86,209 - $115,361
-1,175 Reduced 1.38%
83,714 $8.22 Million
Q1 2020

Apr 15, 2020

SELL
$64.5 - $97.79 $238,327 - $361,334
-3,695 Reduced 4.17%
84,889 $6.47 Million
Q4 2019

Jan 22, 2020

SELL
$72.13 - $90.25 $346,296 - $433,290
-4,801 Reduced 5.14%
88,584 $7.84 Million
Q3 2019

Nov 05, 2019

BUY
$62.98 - $75.72 $92,832 - $111,611
1,474 Added 1.6%
93,385 $7.07 Million
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $169,046 - $216,080
-2,573 Reduced 2.72%
91,911 $6.68 Million
Q1 2019

Apr 08, 2019

SELL
$77.14 - $90.79 $497,861 - $585,958
-6,454 Reduced 6.39%
94,484 $7.61 Million
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $101,905 - $125,677
1,309 Added 1.31%
100,938 $9.31 Million
Q3 2018

Oct 31, 2018

SELL
$88.91 - $98.84 $519,856 - $577,917
-5,847 Reduced 5.54%
99,629 $9.42 Million
Q2 2018

Aug 07, 2018

SELL
$89.78 - $106.23 $488,582 - $578,103
-5,442 Reduced 4.91%
105,476 $9.77 Million
Q1 2018

Apr 20, 2018

SELL
$92.01 - $123.21 $28,155 - $37,702
-306 Reduced 0.28%
110,918 $10.5 Million
Q4 2017

Feb 08, 2018

SELL
$89.56 - $98.21 $28,569 - $31,328
-319 Reduced 0.29%
111,224 $10.8 Million
Q3 2017

Oct 27, 2017

SELL
$69.85 - $89.22 $121,399 - $155,064
-1,738 Reduced 1.53%
111,543 $9.91 Million
Q2 2017

Aug 07, 2017

BUY
N/A
113,281
113,281 $0

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Loring Wolcott & Coolidge Fiduciary Advisors LLP Portfolio

Follow Loring Wolcott & Coolidge Fiduciary Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.